Blog
RSS FeedPosted by Michael Wonder on 30 Sep 2023
Medison Pharma announces public formulary listing of Qinlock (ripretinib) in Canadian provinces: Ontario and Quebec for advanced gastro-intestinal stromal tumour treatment
29 September 2023 - Medison Pharma is pleased to announce the public formulary listing of Qinlock in Canadian provinces: Ontario ...
Posted by Michael Wonder on 08 Mar 2023
Jazz Pharmaceuticals secures eight additional provincial reimbursements for Vyxeos for treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes
8 March 2023 - Jazz Pharmaceuticals announced today that Vyxeos (daunorubicin and cytarabine liposome for injection) is now included on eight ...
Posted by Michael Wonder on 03 Dec 2022
AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan
1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...
Posted by Michael Wonder on 12 Oct 2022
Medical industry advocates urge Ontario to offer cheaper versions of prescription medications
11 October 2022 - Medical industry advocates are urging the Ontario government to offer cheaper versions of certain prescription medications ...
Posted by Michael Wonder on 17 May 2022
Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, join a growing list of provinces providing public drug plan reimbursement for Teva Canada’s Ajovy (fremanezumab), for the preventive treatment of migraine in adults
17 May 2022 - Teva Canada welcomes the recently announced public formulary coverage for Ajovy (fremanezumab) by Ontario, British Columbia, ...
Posted by Michael Wonder on 03 May 2022
Boehringer Ingelheim Canada announces reimbursement for Ofev (nintedanib) in seven public drug plans for the treatment of progressive fibrosing interstitial lung diseases
3 May 2022 - Boehringer Ingelheim is pleased to announce that Ofev (nintedanib), is now available for public reimbursement in Quebec, ...
Posted by Michael Wonder on 21 Apr 2022
Astellas announces reimbursement for Xospata (gilteritinib) in most provinces for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
21 April 2022 - Having access to an additional treatment option offers hope for Canadian adult AML patients with relapsed ...
Posted by Michael Wonder on 02 Mar 2022
ALS Canada marks Rare Disease Day 2022 by calling on Ontario to champion expedited access to ALS therapies
28 February 2022 - The ALS Society of Canada Cana today marks Rare Disease Day 2022 by calling on the ...
Posted by Michael Wonder on 24 Feb 2022
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...
Posted by Michael Wonder on 30 Jan 2022
Baqsimi (nasal glucagon) rescue treatment for severe hypoglycaemia now covered in Ontario
28 January 2022 - Lilly Canada is pleased to announce that as of 31 January 2022, Baqsimi (glucagon nasal powder) ...
Posted by Michael Wonder on 12 Oct 2021
Outdated criteria for drug plan reimbursement obstruct evidence based care
12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...
Posted by Michael Wonder on 25 Sep 2021
Ontario providing access to life changing treatment for cystic fibrosis patients
24 September 2021 - Ontario is now providing coverage for Trikafta, the latest and most effective treatment option for cystic fibrosis ...
Posted by Michael Wonder on 21 Aug 2021
Cystic fibrosis patients, advocates urge Ontario government to provide ‘miracle drug’ funding
20 August 2021 - An Ontario teen living with Cystic Fibrosis and her mother are hoping to shine a light ...
Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...
Posted by Michael Wonder on 29 Apr 2021
Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program
28 April 2021 - Additional provincial coverage expected to follow. ...